Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico

Lung cancer is the second most frequent malignancy in incidence and the leading cause of cancer related mortality. Non-small cell lung cancer (NSCLC) accounts for 85% of the cases and includes three subtypes: lung adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). Ea...

Descripción completa

Detalles Bibliográficos
Autor: Ramos Paradas, Javier
Tipo de recurso: tesis doctoral
Fecha de publicación:2024
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:español
OAI Identifier:oai:docta.ucm.es:20.500.14352/101461
Acceso en línea:https://hdl.handle.net/20.500.14352/101461
Access Level:acceso abierto
Palabra clave:616.24-006.04(043.2)
Piulmones
Lungs
Cancer
Neumología
Oncología
3205.08 Enfermedades Pulmonares
id ES_4e18c91df1fbe1543bff2aa8a9b1ecb4
oai_identifier_str oai:docta.ucm.es:20.500.14352/101461
network_acronym_str ES
network_name_str España
repository_id_str
spelling Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcíticoComprehensive characterization of the molecular genotype and immunophenotype of non-small cell lung cancerRamos Paradas, Javier616.24-006.04(043.2)PiulmonesLungsCancerNeumologíaOncología3205.08 Enfermedades PulmonaresLung cancer is the second most frequent malignancy in incidence and the leading cause of cancer related mortality. Non-small cell lung cancer (NSCLC) accounts for 85% of the cases and includes three subtypes: lung adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). Each variety presents distinct underlying genomic alterations. The prognosis of this disease has been markedly determined by the frequent late stage at diagnosis and the scarcity of effective systemic treatments. Lately, targeted therapy for oncogene driven NSCLCs, and immunotherapy with PD-1/PD-L1 inhibitors have shifted NSCLC management, showing remarkable benefits in treated patients. The benefit fro mimmune checkpoint inhibitors, particularly in the long term, is however not universal but restricted to a subset of patients. The development of predictive biomarkers in this setting has been challenging and recognized as a major unmet need as at present only PD-L1expression is extensively used, although its performance is far from ideal...Universidad Complutense de MadridPaz-Ares Rodríguez, LuzGarrido Martín, Eva MaríaUniversidad Complutense de Madrid20242024-02-1520242024-02-15doctoral thesishttp://purl.org/coar/resource_type/c_db06info:eu-repo/semantics/doctoralThesisapplication/pdfhttps://hdl.handle.net/20.500.14352/101461reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Españolspaopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1014612026-06-02T12:44:21Z
dc.title.none.fl_str_mv Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
Comprehensive characterization of the molecular genotype and immunophenotype of non-small cell lung cancer
title Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
spellingShingle Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
Ramos Paradas, Javier
616.24-006.04(043.2)
Piulmones
Lungs
Cancer
Neumología
Oncología
3205.08 Enfermedades Pulmonares
title_short Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
title_full Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
title_fullStr Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
title_full_unstemmed Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
title_sort Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
dc.creator.none.fl_str_mv Ramos Paradas, Javier
author Ramos Paradas, Javier
author_facet Ramos Paradas, Javier
author_role author
dc.contributor.none.fl_str_mv Paz-Ares Rodríguez, Luz
Garrido Martín, Eva María
Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 616.24-006.04(043.2)
Piulmones
Lungs
Cancer
Neumología
Oncología
3205.08 Enfermedades Pulmonares
topic 616.24-006.04(043.2)
Piulmones
Lungs
Cancer
Neumología
Oncología
3205.08 Enfermedades Pulmonares
description Lung cancer is the second most frequent malignancy in incidence and the leading cause of cancer related mortality. Non-small cell lung cancer (NSCLC) accounts for 85% of the cases and includes three subtypes: lung adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). Each variety presents distinct underlying genomic alterations. The prognosis of this disease has been markedly determined by the frequent late stage at diagnosis and the scarcity of effective systemic treatments. Lately, targeted therapy for oncogene driven NSCLCs, and immunotherapy with PD-1/PD-L1 inhibitors have shifted NSCLC management, showing remarkable benefits in treated patients. The benefit fro mimmune checkpoint inhibitors, particularly in the long term, is however not universal but restricted to a subset of patients. The development of predictive biomarkers in this setting has been challenging and recognized as a major unmet need as at present only PD-L1expression is extensively used, although its performance is far from ideal...
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-02-15
2024
2024-02-15
dc.type.none.fl_str_mv doctoral thesis
http://purl.org/coar/resource_type/c_db06
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/101461
url https://hdl.handle.net/20.500.14352/101461
dc.language.none.fl_str_mv Español
spa
language_invalid_str_mv Español
language spa
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Complutense de Madrid
publisher.none.fl_str_mv Universidad Complutense de Madrid
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407734144696320
score 15.300719

Similares en LA Referencia